AROCELL AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.372 SEK | 0.00% |
|
-1.59% | -14.87% |
| Apr. 18 | Swedish Diagnostics Company AroCell Secures US Patent | MT |
| Feb. 22 | AroCell AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 90.48 | 177.2 | 108.9 | 142.8 | 100.7 | 85.69 | - | - |
| Enterprise Value (EV) 1 | 87.81 | 177.2 | 90.48 | 77.63 | 100.7 | 49.69 | 47.69 | 85.69 |
| P/E ratio | -2.25 x | -7.09 x | - | -2.21 x | -1.68 x | -1.86 x | -3.72 x | - |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 204 x | - | 9.08 x | 3.86 x | 2.34 x | 1.4 x | 1.04 x | 0.8 x |
| EV / Revenue | 198 x | - | 7.54 x | 2.1 x | 2.34 x | 0.81 x | 0.58 x | 0.8 x |
| EV / EBITDA | -5.07 x | - | -3.48 x | -5.45 x | - | -7.2 x | 5.68 x | 4.73 x |
| EV / FCF | -21.8 x | - | -3.21 x | -4.64 x | - | -4.14 x | 23.8 x | - |
| FCF Yield | -4.59% | - | -31.2% | -21.5% | - | -24.1% | 4.19% | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 75,712 | 75,712 | 114,613 | 230,361 | 230,361 | 230,361 | - | - |
| Reference price 2 | 1.195 | 2.340 | 0.9500 | 0.6200 | 0.4370 | 0.3720 | 0.3720 | 0.3720 |
| Announcement Date | 2/21/20 | 2/19/21 | 4/7/22 | 2/23/23 | 4/12/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.443 | - | 12 | 36.99 | 43.04 | 61 | 82.4 | 107.1 |
| EBITDA 1 | -17.34 | - | -25.99 | -14.25 | - | -6.9 | 8.4 | 18.1 |
| EBIT 1 | -20.74 | - | -50.57 | -59.3 | -59.78 | -51.2 | -31.2 | -1.7 |
| Operating Margin | -4,680.81% | - | -421.58% | -160.34% | -138.91% | -83.93% | -37.86% | -1.59% |
| Earnings before Tax (EBT) 1 | -20.74 | - | - | -58.97 | -59.3 | -51 | -32 | - |
| Net income 1 | -20.74 | -24.05 | - | -58.97 | -59.3 | -51 | -32 | - |
| Net margin | -4,680.81% | - | - | -159.45% | -137.78% | -83.61% | -38.83% | - |
| EPS 2 | -0.5300 | -0.3300 | - | -0.2800 | -0.2600 | -0.2000 | -0.1000 | - |
| Free Cash Flow 1 | -4.032 | - | -28.21 | -16.72 | - | -12 | 2 | - |
| FCF margin | -910.16% | - | -235.13% | -45.2% | - | -19.67% | 2.43% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 23.81% | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/21/20 | 2/19/21 | 4/7/22 | 2/23/23 | 4/12/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 7.77 | 6.349 | 10.4 | 12.47 | 11.05 | 11.78 | 10.7 | 9.511 | 12.3 | 15.1 | 16.5 | 17.1 |
| EBITDA 1 | - | - | -10.62 | -10.94 | -5.99 | - | - | - | - | - | -3.2 | -2.4 | -1 | -0.3 |
| EBIT 1 | - | - | -15.7 | -16.01 | -11.07 | -16.53 | -13.67 | -15.48 | -13.26 | -17.36 | -14.3 | -13.4 | -12.1 | -11.4 |
| Operating Margin | - | - | -201.99% | -252.23% | -106.41% | -132.53% | -123.68% | -131.51% | -123.97% | -182.57% | -116.26% | -88.74% | -73.33% | -66.67% |
| Earnings before Tax (EBT) | - | -20.25 | -15.7 | -16.02 | - | - | - | - | - | - | - | - | - | - |
| Net income | -17.52 | - | -15.49 | -15.9 | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | -199.32% | -250.4% | - | - | - | - | - | - | - | - | - | - |
| EPS | -0.1600 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/12/21 | 4/7/22 | 4/29/22 | 8/17/22 | 10/27/22 | 2/23/23 | 5/3/23 | 8/23/23 | 11/2/23 | 4/12/24 | - | - | - | - |
1SEK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 2.66 | - | 18.4 | 65.2 | - | 36 | 38 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -4.03 | - | -28.2 | -16.7 | - | -12 | 2 | - |
| ROE (net income / shareholders' equity) | -30.7% | - | -37.1% | -26.8% | - | -37% | -32% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.25 | - | - | 3.02 | - | 2 | 2 | - |
| Capex / Sales | 55.3% | - | - | 8.18% | - | 3.28% | 2.43% | - |
| Announcement Date | 2/21/20 | 2/19/21 | 4/7/22 | 2/23/23 | 4/12/24 | - | - | - |
1SEK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.87% | 7.82M | |
| +1.51% | 42.75B | |
| +47.75% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- AROC Stock
- Financials AroCell AB
